

mondoBIOTECH holding AG (SIX:RARE): United States FDA grants mondoBIOTECH's Medicinal Product Candidate DasKloster0210 the Orphan Drug Designation for the treatment of Chronic Beryllium Disease.

Stans, 14 September 2010 – mondoBIOTECH holding AG (SIX: RARE) announces today that the United States FDA has granted the Orphan Drug Designation for the treatment of Chronic Beryllium Disease to its medicinal product candidate, the human peptide DasKloster0210.

"We are very pleased that our product candidate for Chronic Beryllium Disease is now listed in the official US register of Orphan Drugs. This means a global validation of our "Finding Treatments for Rare Diseases" mission and another important milestone in the growth of our company" commented Ruggero Gramatica, CEO of mondoBIOTECH.

"This grant arrives at the perfect moment in our development process," says Dorian Bevec, CSO, "as DasKloster0210 is another one of our new series of human peptides redirected in new indications and a validation of our Search & Match strategy for creating pipeline in rare diseases."

Orphan Drug Designation (ODD) is granted for products that are intended to treat life-threatening or chronically debilitating conditions affecting no more than 5 in 10,000 persons in Europe and less than 200 000 patients in the United States. Further criteria include the potential of the product to provide significant patient benefit over available treatment, or to fill an unmet medical need where no other treatment exists.

About Chronic Beryllium Disease and DasKloster0210

Chronic Beryllium Disease ("CBD"), also known as berylliosis, is an occupational hypersensitivity disorder caused by continued beryllium exposure. It is characterised by non-caseating, non-necrotising granulomata within affected organs, most frequently lung and skin. The main symptoms include dry coughing, fatigue, weight loss, chest pain, and increasing shortness of breath. Inhalation of beryllium dust or fumes and dermal contact with beryllium and its compounds represent the primary ways of human beryllium uptake. Genetic predisposition seems to play an important role in CBD development. The diagnosis is based on the association of beryllium exposure and sensitisation with symptomatic disease including abnormal lung function and chest radiographs.

DasKloster0210 is an endogenous human peptide initially described in the year 1957. To date, more than 4'000 scientific literature articles describe the immunomodulatory, anti-inflammatory, and antipyretic effects of DasKloster0210. mondoBIOTECH believes that DasKloster0210 will have beneficial effects for patients affected by CBD.

About Mondobiotech

mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases.

For further information please contact:

mondoBIOTECH holding AG
Investor Relations, Mr. Paolo Bassanini
Das Kloster
Mürgstrasse 18
CH-6370 Stans
Tel.: +41 (0) 840 200 010
Fax: +41 (0) 840 200 011
investor@mondobiotech.com
www.mondobiotech.com

Disclaimer

The foregoing release may contain forward-looking statements. The words "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "will", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG's forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward-looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. mondoBIOTECH holding AG is providing the information in this press release

as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Personal Information

This email is from mondoBIOTECH holding AG. The email and any files transmitted with it are intended solely for the use of the individual or entity to which they are addressed. Any unauthorized dissemination or copying of this email or its attachments, is strictly prohibited and may be illegal. If you have received the email in error please delete it from your system.